Get started
Author

Iris Fernández-Lázaro

Observed names: Fernández-Lázaro, Iris, I. Fernández-Lázaro, Iris Fernández Lázaro, Iris Fernández‐Lázaro
ORCID: 0009-0004-2544-5206
Observed ORCID: 0009-0004-2544-5206
OpenAlex ID: A5099430232
Redefining migraine prevention: early treatment with anti-CGRP monoclonal antibodies enhances response in the real world
2024 · Edoardo Caronna, Victor José Gallardo, et al. · Journal of Neurology Neurosurgery & Psychiatry · 64
PDF
Long-Term Effectiveness and Persistence Factors of Anti-CGRP Monoclonal Antibodies in Migraine: 2-Year Results From the EUREkA Cohort
2026 · Edoardo Caronna, Rut Mas-de-les-Valls, et al. · Neurology · 11
RE‐START : Exploring the effectiveness of anti‐calcitonin gene‐related peptide resumption after discontinuation in migraine
2024 · Celia Romero del Rincón, Alicia Gonzalez‐Martinez, et al. · European Journal of Neurology · 9
PDF
Atogepant after anti-CGRP monoclonal antibodies failure in migraine: a multicenter real-world study of effectiveness, safety, persistence and predictors of response
2025 · Albert Muñoz-Vendrell, Sergio Campoy-Díaz, et al. · The Journal of Headache and Pain · 8
Evaluation of the concomitant use of prophylactic treatments in patients with migraine under anti‐calcitonin gene‐related peptide therapies: The PREVENAC study
2024 · Ana Beatriz Gago‐Veiga, Noelia Lopez‐Alcaide, et al. · European Journal of Neurology · 4
PDF
Is achieving higher standards in real-world migraine care feasible with anti-CGRP monoclonal antibodies preventive therapies?: Insights from the EUREkA cohort
2026 · Edoardo Caronna, Rut Mas-de-les-Valls, et al. · Cephalalgia · 1
Long-Term Effectiveness and Persistence Factors of Anti-CGRP Monoclonal Antibodies in Migraine: 2-Year Results From the EUREkA Cohort
2026 · Edoardo Caronna, Rut Mas-de-les-Valls, et al. · Neurology · 1
PDF
Atogepant for migraine in real-world clinical practice: Insights from a large multicentre study in a treatment-resistant population (GEMA project)
2026 · Ana Beatriz Gago-Veiga, Ana Belen Lopez-Rodriguez, et al. · Cephalalgia · 1
Long-term atogepant for treatment-resistant migraine in real-world clinical practice: 12-month results (gema project)
2026 · Ana Beatriz Gago-Veiga, Ana Belen Lopez-Rodriguez, et al. · The Journal of Headache and Pain
Rimegepant for migraine prevention in clinical practice: A multicenter study including patients with prior anti-CGRP monoclonal antibody failure (GEMA project)
2026 · Ana Beatriz Gago-Veiga, Ana Belen Lopez-Rodriguez, et al. · Cephalalgia
ESTELA‐Study: Long‐Term Effectiveness and Safety of Anti‐Calcitonin Gene‐Related Peptide Monoclonal Antibodies in Real‐World Clinical Practice
2026 · Alba Somovilla, Iris Fernández‐Lázaro, et al. · Brain and Behavior
Effectiveness and Risk of Recurrence of Pulsed Radiofrequency in Trigeminal Neuralgia and Chronic Cluster Headache
2026 · Marta Domínguez, Alicia Gonzalez-Martinez, et al. · Revista de Neurología
PDF
Changes in plasma glutamate in hemodialysis-related-headache patients: A pilot study
2026 · M. Sobrado, P. Alcantara-Miranda, et al. · Neurología
Atogepant after anti-CGRP monoclonal antibodies failure in migraine: a multicenter real-world study of effectiveness, safety, persistence and predictors of response
2026 · Muñoz-Vendrell, Albert, Campoy-Díaz, Sergio, et al. · Figshare
Additional file 1 of Atogepant after anti-CGRP monoclonal antibodies failure in migraine: a multicenter real-world study of effectiveness, safety, persistence and predictors of response
2026 · Muñoz-Vendrell, Albert, Campoy-Díaz, Sergio, et al. · Figshare
Additional file 2 of Atogepant after anti-CGRP monoclonal antibodies failure in migraine: a multicenter real-world study of effectiveness, safety, persistence and predictors of response
2026 · Muñoz-Vendrell, Albert, Campoy-Díaz, Sergio, et al. · Figshare
Additional file 3 of Atogepant after anti-CGRP monoclonal antibodies failure in migraine: a multicenter real-world study of effectiveness, safety, persistence and predictors of response
2026 · Muñoz-Vendrell, Albert, Campoy-Díaz, Sergio, et al. · Figshare
Works count: 17
Citation count: 99
H-index: 4
I10-index: 2
Year
Topic
Type